Royalty Pharma plc (RPRX) Stock
RPRX has an Alpha Score of 57 out of 100 (moderate), computed on Nov 7, 2026 from 3 of 4 sub-scores. Company insiders reported 0 open-market buys and 7 sales on SEC Form 4 in the 90 days to Nov 9, 2026. Its trailing P/E ratio is 47.4 and its net margin 32.1% (key statistics as of Nov 5, 2026).
What is RPRX's Alpha Score?
How it works →Alpha Score of 57 reflects moderate overall profile with strong momentum, weak value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 7, 2026
A rules-based research rating, not a recommendation to buy or sell.
Are Royalty Pharma plc insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 5, 26 | Urist Marshall | EVP, Research & Investments | SELL | 4.1K | $236K |
| Sep 28, 26 | Urist Marshall | EVP, Research & Investments | SELL | 4.1K | $239K |
| Sep 22, 26 | Hite Christopher | EVP & Chairman, Partnering | SELL | 96.1K | $5.6M |
| Sep 22, 26 | Hite Christopher | EVP & Chairman, Partnering | SELL | 3.9K | $231K |
| Aug 18, 26 | Hite Christopher | EVP & Chairman, Partnering | SELL | 100.0K | $6.0M |
| Aug 13, 26 | Coyne Terrance P. | EVP & CFO | SELL | 9.2K | $541K |
| Aug 13, 26 | Coyne Terrance P. | EVP & CFO | SELL | 1.8K | $105K |
| May 26, 26 | Coyne Terrance P. | EVP & CFO | SELL | 64.4K | $3.5M |
| May 20, 26 | Urist Marshall | EVP, Research & Investments | SELL | 13.7K | $722K |
| May 14, 26 | Urist Marshall | EVP, Research & Investments | SELL | 13.7K | $726K |
SEC Form 4 filings as of Nov 9, 2026
See cluster-buy signals across all tickers →What are RPRX's key statistics?
Key statistics as of Nov 5, 2026
How does RPRX's valuation compare with the Healthcare sector?
| Metric | RPRX | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 47.4 | 29.7 | 114 |
| Net margin | 32.14% | 3.62% | 174 |
| Return on equity | 12.25% | 2.96% | 200 |
| Dividend yield (payers) | 2.96% | 1.59% | 55 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 10, 2026). P/E excludes loss-making companies.
RPRX price chart
Powered by TradingViewWhat does Royalty Pharma plc do?
Royalty Pharma plc is the world's largest buyer of biopharmaceutical royalties and a leading funder of innovation in the life sciences sector. The company acquires royalties entitling it to payments based on net sales of approved therapies and development-stage product candidates, partnering with innovators from academic institutions, research hospitals, nonprofits, small and mid-cap biotechnology firms, and major global pharmaceutical companies. Its extensive portfolio encompasses royalties on more than 35 commercial products addressing conditions such as cystic fibrosis (e.g., Vertex's Trikafta and Kalydeco), multiple sclerosis (e.g., Biogen's Tysabri and Spinraza), blood cancers (e.g., Imbruvica from AbbVie and Johnson & Johnson), prostate cancer (e.g., Xtandi from Astellas and Pfizer), ATTR amyloidosis (e.g., Alnylam's Amvuttra), and schizophrenia (e.g., Bristol Myers Squibb's Cobenfy), alongside over 20 pipeline assets targeting vitiligo, Hunter syndrome, lupus, hereditary angioedema, and cardiovascular disease. Royalty Pharma plc provides tailored non-dilutive funding solutions to support late-stage clinical trials and product launches, holding a dominant position with significant global market share in biopharma royalty transactions. Founded in 1996 and headquartered in New York, NY, it operates at the intersection of science, medicine, and investing to accelerate bio-innovation.